(78 days)
No
The document does not mention AI, DNN, or ML. While it mentions advanced image processing techniques like AIDR 3D Enhanced and PURE ViSION Optics, these are not explicitly stated to be AI/ML-based in this summary.
No
The device is described as an imaging system (CT System) used to acquire and display cross-sectional volumes of the body for diagnostic purposes, not for treatment.
Yes
The device is indicated to acquire and display cross-sectional volumes of the body and produces images of diagnostic quality, used by trained physicians, which clearly indicates its purpose in diagnosing medical conditions.
No
The device description explicitly states it is an "80-row CT System" and mentions hardware components like "PURE Vision Optics". The performance studies also evaluate hardware-related characteristics like spatial resolution, CT number, and noise properties.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens taken from the human body, such as blood, urine, or tissue, to provide information for diagnosis, monitoring, or screening.
- Device Function: The description clearly states that this device is a Computed Tomography (CT) system used to acquire and display cross-sectional volumes of the whole body. This is an imaging modality that works by sending X-rays through the body and detecting how they are absorbed, not by analyzing biological specimens.
- Intended Use: The intended use is to acquire and display images for diagnostic purposes, which is typical for imaging devices, not IVDs.
- Lack of Specimen Analysis: There is no mention of analyzing any biological specimens or performing tests on samples taken from the body.
Therefore, this device falls under the category of medical imaging devices, not In Vitro Diagnostic devices.
N/A
Intended Use / Indications for Use
This device is indicated to acquire and display cross-sectional volumes of the whole body, to include the head.
The Aquilion Prime SP has the capability to provide volume sets. These volume sets can be used to perform specialized studies, using indicated software, by a trained and qualified physician.
Product codes
JAK
Device Description
The Aquilion Prime SP TSX-303B/1 is an 80-row CT System that is intended to acquire and display cross-sectional volumes of the whole body, including the head. This system is based upon the technology and materials of previously marketed Toshiba CT systems.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Computed Tomography x-ray system
Anatomical Site
whole body, to include the head
Indicated Patient Age Range
Not Found
Intended User / Care Setting
trained and qualified physician / Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Quantitative Dose Reduction and Spatial Resolution Evaluation: A dose reduction study was conducted using AIDR 3D Enhanced. It supported a dose reduction claim with the range 51% to 75% while simultaneously preserving low contrast detectability and high contrast spatial resolution.
PURE ViSION Optics Quantitative LCD and Noise Improvement: Studies were conducted comparing the subject device with PURE Vision Optics versus the predicate device to assess dose reduction and LCD/Noise improvements using filtered backprojection (FBP) on both systems. The results demonstrated a quantitative dose reduction of 20%-31%, improvements in low contrast detectability for head (range 13%-19%), improvements in low contrast detectability for body (range 15%-22%) and noise reduction of 13% at the same dose as evaluated via model observer studies (MITA-FDA LCD Head and MITA-FDA LCD Body phantoms).
Representative diagnostic images, reviewed by an American Board Certified Radiologist, including head, chest, abdomen and peripheral exams were also obtained using the subject device which demonstrates that the device produces images of diagnostic quality and; therefore, performs as intended.
Key Metrics
Quantitative Dose Reduction and Spatial Resolution Evaluation: 51% to 75% does reduction.
PURE ViSION Optics Quantitative LCD and Noise Improvement: 20%-31% quantitative dose reduction, 13%-19% improvements in low contrast detectability for head, 15%-22% improvements in low contrast detectability for body, and 13% noise reduction.
Predicate Device(s)
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.1750 Computed tomography x-ray system.
(a)
Identification. A computed tomography x-ray system is a diagnostic x-ray system intended to produce cross-sectional images of the body by computer reconstruction of x-ray transmission data from the same axial plane taken at different angles. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II.
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
Toshiba Medical Systems Corporation % Orlando Tadeo, Jr. Regulatory Affairs Manager Toshiba America Medical Systems, Inc. 2441 Michelle Drive TUSTIN CA 92780
October 6, 2017
Re: K172188
Trade/Device Name: Aquilion Prime SP, TSX-303B/1, v8.4 Regulation Number: 21 CFR 892.1750 Regulation Name: Computed tomography x-ray system Regulatory Class: II Product Code: JAK Dated: July 19, 2017 Received: July 20, 2017
Dear Mr. Tadeo:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education (DICE) at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education (DICE) at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely,
Michael D. O'Hara For
Robert Ochs. Ph.D. Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known)
Device Name
Aquilion Prime SP, TSX-303B/1, v8.4
Indications for Use (Describe)
This device is indicated to acquire and display cross-sectional volumes of the whole body, to include the head.
The Aquilion Prime SP has the capability to provide volume sets. These volume sets can be used to perform specialized studies, using indicated software/hardware, by a trained and qualified physician.
Type of Use (Select one or both, as applicable)
ال Prescription Use (Part 21 CFR 801 Subpart D)
_ Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) SUMMARY
-
- SUBMITTER'S NAME: Toshiba Medical Systems Corporation 1385 Shimoishigami Otawara-Shi, Tochigi-ken, Japan 324-8550
-
- OFFICIAL CORRESPONDENT: Naofumi Watanabe Senior Manager, Regulatory Affairs and Vigilance
-
- ESTABLISHMENT REGISTRATION: 9614698
4. CONTACT PERSON:
Orlando Tadeo, Jr. Manager, Regulatory Affairs Toshiba America Medical Systems, Inc 2441 Michelle Drive Tustin, CA 92780 (714) 669-7459
-
- Date Prepared:
September 27, 2017
- Date Prepared:
-
- TRADE NAME(S): Aquilion Prime SP, TSX-303B/1, v8.4
-
- COMMON NAME: System, X-ray, Computed Tomography
-
- DEVICE CLASSIFICATION: Class II (per 21 CFR 892.1750)
-
- PRODUCT CODE / DESCRIPTION: JAK – System, Computed Tomography
Image /page/3/Picture/14 description: The image shows the text "TOSHIBA AMERICA MEDICAL SYSTEMS" in a bold, sans-serif font. The text is arranged on a single line and is centrally aligned. The words are all capitalized and evenly spaced.
2441 Michelle Drive, Tustin, CA 92780 / 800.421.1968 / medical.toshiba.com
Image /page/3/Picture/16 description: The image shows the Canon Group logo. The word "Canon" is in red, and the word "GROUP" is in black. The Canon logo is a stylized version of the word "Canon", with a unique design for the letter "O".
4
10. PERFORMANCE STANDARD:
This device conforms to applicable Performance Standards for Ionizing Radiation Emitting Products [21 CFR, Subchapter J, Part 1020]
11. PREDICATE DEVICE:
| Product | Marketed by | 510(k) Number | Clearance Date |
|---|---|---|---|
| Aquilion PRIME, | |||
| TSX-303A/A, /B and /F, v6.00 | |||
| (Primary Predicate Device) | Toshiba America | ||
| Medical Systems | K141741 | November 11, 2014 | |
| Aquilion Lightning SP | |||
| TSX-036A/1, v8.4 | Toshiba America | ||
| Medical Systems | K170019 | February 2, 2017 |
12. REASON FOR SUBMISSION:
Modification of a cleared device
13. DEVICE DESCRIPTION:
The Aquilion Prime SP TSX-303B/1 is an 80-row CT System that is intended to acquire and display cross-sectional volumes of the whole body, including the head. This system is based upon the technology and materials of previously marketed Toshiba CT systems.
14. INDICATIONS FOR USE:
This device is indicated to acquire and display cross-sectional volumes of the whole body, to include the head.
The Aquilion Prime SP has the capability to provide volume sets. These volume sets can be used to perform specialized studies, using indicated software, by a trained and qualified physician.
15. SUBSTANTIAL EQUIVALENCE:
The subject device is substantially equivalent to the Aquilion PRIME, TSX-303A/A, /B and /F v6.00, which received premarket clearance under K141741 and is marketed by Toshiba America Medical Systems. The Aquilion Prime SP TSX-303B/1, v8.4, incorporates modifications to the cleared device which include changes to the current detector (new wedge filter and new DAS board), modifications to previously cleared optional software applications in order to realize workflow improvements and addition of previously cleared optional software features. These changes do not affect the safety or efficacy of the cleared device, as demonstrated in performance testing. The method of operation and manufacturing process remain unchanged from the cleared device. See below for a brief comparison of the technological characteristics between the subject and the predicate devices:
5
| Item | Aquilion Prime SP
TSX-303B/1, v8.4 | Aquilion PRIME
TSX-303A/A,/B and /F, v6.00 |
|--------------------------------------------------------------|--------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| 510(k) Number | This submission | K141741 |
| Detector | 896 channels × 80 rows
PURE Vision | 896 channels × 80 rows
PURE Vision |
| Number of detector
elements | 0.5 mm x 80 rows | 0.5 mm x 80 rows |
| Maximum scan
length/rotation | 40 mm/rotation | 40 mm/rotation |
| FOV (Field of View) | 320/500 mm
in diameter | 180/240/320/400/500 mm
in diameter |
| Wedge filter types | Two types | Three types |
| PURE Vision Optics* | Standard | N/A |
| Processing capability | Hexa-core Xeon
32GB memory or more | Quad-core Xeon
12GB memory or more |
| Image reconstruction time
(Max. speed) | Up to 50 images/s (0.02 s/image)
Up to 70 images/s (0.014 s/image)
- with optional upgrade | Up to 30 images/s (0.033 s/image)
Up to 60 images/s (0.016 s/image) - with optional upgrade |
| Extended Field of View | Available | Not Available |
Modifications to previously cleared software options:
| Application | Comment |
|---|---|
| Variable Helical Pitch (vHP) | Workflow improvements: 3-phase vHP available |
| and for ECG-gated helical scan phase, Modulation | |
| can be specified and SUREExposure3D is enabled. | |
| Previously cleared under K170019 | |
| Dual Energy System Package | Workflow improvement: DE clinical application |
| can be executed during scanning. | |
| Previously cleared under K170019 | |
| SEMAR | |
| (Single Energy Metal Artifact Reduction) | Implementation of Volume ECG-gated scan, |
| previously cleared under K170019 |
Previously cleared software options being implemented to the modified device:
| 4D Cerebral Artery Morphological Analysis | Previously cleared under K142465 |
|---|---|
| SURE Subtraction Lung | Previously cleared under K133324 |
| Scan Protocol Management | Previously cleared under K142465 |
6
*PURE Vision Optics, based upon the new wedge filters in combination with the PUREVision detector, afford the system with an optimized beam spectrum and the filtration of low energy photons for a more homogeneous x-ray spectrum. Previously cleared under K170177
16. SAFETY:
The device is designed and manufactured under the Quality System Regulations as outlined in 21 CFR § 820 and ISO 13485 Standards. This device is in conformance with the applicable parts of the IEC60601-1, IEC60601-1-1, IEC60601-1-2, IEC60601-1-4, IEC60601-1-6, IEC60601-1-6, IEC60601-2-28, IEC60601-2-32, IEC60601-2-44, IEC60825-1, IEC62304, IEC62366, NEMA PS 3.1-3.18, NEMA XR-25 NEMA XR-26 and NEMA XR-29. Additionally, this device complies with all applicable requirements of the radiation safety performance standards, as outlined in 21 CFR §1010 and §1020.
17. TESTING
Risk analysis and verification/validation testing conducted through bench testing are included in this submission which demonstrates that the requirements for the modifications made to the system have been met. The modified system was evaluated to assess spatial resolution, axial slice thickness/slice sensitivity profile, CT number magnitude/uniformity, noise properties, low contrast detectability and contrast-to-noise ratio performance and it was determined that the subject device demonstrates equivalent or slightly improved image quality characteristics.
Quantitative Dose Reduction and Spatial Resolution Evaluation
A dose reduction study was conducted using AIDR 3D Enhanced and based on the results, a dose reduction claim with the range 51% to 75% is supported while simultaneously preserving low contrast detectability and high contrast spatial resolution
PURE ViSION Optics Quantitative LCD and Noise Improvement
Studies were conducted comparing the subject device with PURE Vision Optics versus the predicate device to assess dose reduction and LCD/Noise improvements using filtered backprojection (FBP) on both systems. The results of the studies demonstrated a quantitative dose reduction of 20%-31%, improvements in low contrast detectability for head (range 13%-19%), improvements in low contrast detectability for body (range 15%-22%) and noise reduction of 13% at the same dose as evaluated via model observer studies (MITA-FDA LCD Head and MITA-FDA LCD Body phantoms).
Representative diagnostic images, reviewed by an American Board Certified Radiologist, including head, chest, abdomen and peripheral exams were also obtained using the subject device which demonstrates that the device produces images of diagnostic quality and; therefore, performs as intended.
Software Documentation for a Moderate Level of Concern, per the FDA guidance document, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices Document" issued on May 11, 2005, is included as part of this submission.
Cybersecurity documentation, per the FDA cybersecurity premarket guidance document "Content of Premarket Submissions for Management of Cybersecurity in Medical Devices " issued on October 2, 2014, is also included as part of this submission.
7
Additionally, testing of the modified system was conducted in accordance with the applicable standards published by the International Electrotechnical Commission (IEC) for Medical Devices and CT Systems.
18. CONCLUSION
The modifications incorporated into the Aquilion Prime SP TSX-303B/1, v8.4 do not change the indications for use or the intended use of the device. Based upon bench testing, representative clinical images, successful completion of software validation and application of risk management and design controls, it is concluded that the subject device has demonstrated substantial equivalence to the predicates and is safe and effective for its intended use.